FAQ on HeartBeam Inc.'s VALID-ECG Study Results and 12-Lead ECG Technology
Summary
What is HeartBeam Inc.’s 12-lead ECG technology?
HeartBeam’s 12-lead ECG technology is a cable-free, credit card-sized device designed to capture the heart’s electrical signals from three dimensions, providing hospital-grade cardiac insights outside medical facilities.
What were the results of the VALID-ECG study?
The VALID-ECG study showed that HeartBeam’s synthesized 12-lead ECG technology achieved a 93.4% diagnostic agreement with standard 12-lead ECGs for arrhythmia assessment.
Who presented the VALID-ECG study results?
Dr. Thomas Deering of Piedmont Heart Institute presented the results during the Heart Rhythm Society’s annual conference.
What is the significance of HeartBeam’s 12-lead ECG technology?
This technology aims to transform cardiac care by enabling portable, accurate ECG monitoring anywhere, thus allowing for early detection and management of cardiac conditions outside traditional medical settings.
When does HeartBeam plan to commercialize its 12-lead ECG technology?
HeartBeam plans to commercialize its 12-lead ECG technology following anticipated FDA clearance.
Where can I find more information about HeartBeam Inc.?
For more information, visit www.HeartBeam.com or the company’s newsroom at https://ibn.fm/BEAT.
How does HeartBeam’s technology compare to standard 12-lead ECGs?
HeartBeam’s technology offers a portable, cable-free alternative to standard 12-lead ECGs with a 93.4% diagnostic agreement, making it a viable option for remote cardiac monitoring.
What patents does HeartBeam hold?
HeartBeam holds 13 U.S. and 4 international-issued patents related to its technology enablement for portable ECG monitoring.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 118791